1. |
Mundy GR. Mechanisms of bone metastasis 〔J〕. Cancer,1997; 80(8 Suppl)∶1546.
|
2. |
Paget S. The distribution of secondary growths in cancer of the breast 〔J〕. Lancet, 1889; 1(5)∶571.
|
3. |
Mundy GR, Yoneda T. Mechanisms of bone metastasis.In:Orr FW, Singh GN, eds. Bone Metastasismechanisms and pathophysiology〔M〕. Austin, Texsas: R.G. Landes Co., 1996∶1-16.
|
4. |
Crichton MB, Nichols JE, Zhao Y, et al. Expression of transcripts of interleukin6 and related cytokines by human breast tumors,breast cancer cells,and adipose stromal cells 〔J〕.Mol Cell Endocrinol,1996; 118(1-2)∶215.
|
5. |
Lacroix M, Siwek B, Marie PJ, et al. Production and regulation of interleukin 11 by breast cancer cells 〔J〕.Cancer Lett, 1998; 127(1-2)∶29.
|
6. |
Shevrin DH, Kukreja SC, Ghosh L, et al. Development of skeletal metastasis by human prostate cancer in athymic nude mice 〔J〕. Clin Exp Metastasis,1998; 6(5)∶401.
|
7. |
Arguello F, Baqqs RB, Frantz CN, et al. A murine model of experimental metastasis to bone and bone marrow 〔J〕. Cancer Res,1988; 48(23)∶6876.
|
8. |
Arguello F, Furlanetto RW, Baggs RB, et al. Incidence and distribution of experimental metastasis in mutant mice with defective organ microenvironments 〔J〕. Cancer Res, 1992; 52(8)∶2304.
|
9. |
Sasaki A, Alcalde RE, Nishiyama A, et al. Angiogenesis inhibitor TNP470 inhibits human breast cancer osteolytic bone metastasis in nude mice trough the reduction of bone resorption 〔J〕. Cancer Res, 1998; 58(1)∶462.
|
10. |
Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase2 〔J〕.J Clin Invest, 1997; 99(10)∶2509.
|
11. |
Yoneda T, Michigami T, Yi B, et al. Actions of Bisphosphonate on bone metastasis in animal models of breast carcinoma 〔J〕. Cancer, 2000; 88(Suppl)∶2979.
|
12. |
Guise TA. Molecular mechanisms of osteolytic bone metastasis 〔J〕. Cancer, 2000; 88(Suppl)∶2892.
|
13. |
Kjonniksen I, Breistoi K, Fodstad O,et al. Site dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin 〔J〕. Cancer Res, 1992; 52(5)∶1374.
|
14. |
Arguello F, Baggs RB, Eskenazi AE, et al. Vascular anatomy and organspecific tumor growth as critical factors in the development of metastasis and their distribution among organs 〔J〕. Int J Cancer, 1991; 48(4)∶583.
|
15. |
Nicolson GL. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis 〔J〕. Exp Cell Res, 1993; 204(2)∶171.
|
16. |
Kjonniksen I, Winderen M, Bruland O, et al. Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats 〔J〕. Cancer Res, 1994; 54(7)∶1715.
|
17. |
Wang CY, Chang YW. A model for osseous metastasis of human breast cancer established by intrafemur injection of the MDAMB435 cells in nude mice 〔J〕. Anticancer Res, 1997; 17(4A)∶2471.
|
18. |
Price JE, Polyzos A, Zhang RD, et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice 〔J〕. Cancer Res, 1990; 50(3)∶717.
|
19. |
Lelekakis M, Moseley JM, Martin TJ, et al. A novel orthotopic model of breast cancer metastasis to bone 〔J〕. Clin Exp Metastasis,1999; 17(2)∶163.
|
20. |
Hoffman RM. Orthotopic metastatic mouse models for anticancer drug and evaluation: a bridge to the clinic 〔J〕. Invest New Drugs, 1999; 17(4)∶343.
|
21. |
Kurebayashi J, Nukatsuka M, Fujioka A, et al. Postsurgerical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice 〔J〕. Clin Cancer Res, 1997; 3(5)∶653.
|